⚖️ Weight Loss • 2026

Best Peptides for Weight Loss

📄 7 PubMed citations

Six weight loss peptides ranked by clinical evidence — from FDA-approved GLP-1 agonists to research-grade compounds.

Build your own printable peptide tracker

A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →
Short answer

For weight loss, GLP-1 receptor agonists are the most evidence-backed peptides: tirzepatide outperforms semaglutide in head-to-head data, and retatrutide leads on efficacy (25.0% mean weight loss at 80 weeks in Phase 3 TRIUMPH-1, not yet FDA-approved). All effective options require ongoing use, alongside diet and exercise.

Weight Loss by the Numbers

Clinical trial data tells a clear story: GLP-1 agonists dominate weight loss outcomes. Here's how the peptides compare on their primary efficacy measure — percentage of body weight lost:

Average Weight Loss from Clinical Trials

Retatrutide (12mg)
25.0% (80 wk)
Tirzepatide (15mg)
20.9% (72 wk)
Semaglutide (2.4mg)
14.9% (68 wk)
Tesamorelin
Visceral fat only
CJC-1295/Ipamorelin
No trials
AOD-9604
Unproven

Sources: STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), TRIUMPH-1 (Eli Lilly 2026) for retatrutide Phase 3. Trial durations vary — not directly comparable.

⚠️

Cross-trial comparison caveat: These numbers come from different trials with different populations, durations, and endpoints. Direct comparison is approximate. The only head-to-head data is SURMOUNT-5 (tirzepatide vs semaglutide), which confirmed tirzepatide's superiority.

Rankings by Evidence Strength

#1

Tirzepatide (Mounjaro® / Zepbound®)

Dual GIP/GLP-1 Receptor Agonist • FDA-Approved

Tirzepatide targets both GLP-1 and GIP receptors (a dual-agonist approach). The SURMOUNT-1 trial (n=2,539; PMID 35658024) reported 20.9% mean body weight loss at the 15mg dose over 72 weeks versus 3.1% on placebo (treatment-regimen estimand).

In the open-label head-to-head SURMOUNT-5 trial (n=751; PMID 40353578), tirzepatide at its maximum tolerated dose (10 or 15mg) produced 20.2% mean weight loss at 72 weeks vs 13.7% with semaglutide (1.7 or 2.4mg; P<0.001).

Weight Loss: 20.9% (72 wk)
FDA Status: Approved (weight loss + T2D)
Route: Weekly SubQ injection
Trial: SURMOUNT-1, n=2,539
#2

Semaglutide (Wegovy® / Ozempic®)

GLP-1 Receptor Agonist • FDA-Approved

The drug that launched the GLP-1 revolution. Semaglutide 2.4mg produced 14.9% weight loss in STEP 1 (n=1,961, 68 weeks; PMID 33567185). It also has cardiovascular outcome data: in the SELECT trial (PMID 37952131), semaglutide lowered major adverse cardiovascular events versus placebo (6.5% vs 8.0%; hazard ratio 0.80) in adults with overweight or obesity and preexisting cardiovascular disease.

Weight Loss: 14.9% (68 wk)
FDA Status: Approved (weight loss + T2D)
Route: Weekly SubQ injection
Trial: STEP 1, n=1,961
#3

Retatrutide

Triple GIP/GLP-1/Glucagon Receptor Agonist • Phase 3 (TRIUMPH-1 reported)

The triple-agonist approach adds glucagon receptor activation (increases energy expenditure) to the dual GIP/GLP-1 mechanism. Phase 3 TRIUMPH-1 (NEJM 2026, PMID 42814954) reported a 25.0% mean weight loss at the 12mg dose over 80 weeks versus 3.9% on placebo (treatment-regimen estimand), above the 24.2% at 48 weeks from the Phase 2 trial (n=338; PMID 37366315).

TRIUMPH-1 has reported; the broader Phase 3 program continues. Not yet FDA-approved as of mid-2026.

Weight Loss: 25.0% (80 wk, TRIUMPH-1)
FDA Status: Phase 3 reported; not yet approved
Route: Weekly SubQ injection
Trial: TRIUMPH-1 (Phase 3, 80 wk)
#4

Tesamorelin (Egrifta®)

GHRH Analog • FDA-Approved (HIV lipodystrophy)

Tesamorelin stimulates growth hormone release and is FDA-approved specifically for reducing visceral adipose tissue in HIV-associated lipodystrophy. Its target is visceral fat rather than the number on the scale — it's a body composition drug, not a weight loss drug.

Visceral Fat: Reduced (approved indication)
FDA Status: Approved (HIV lipodystrophy only)
Route: Daily SubQ injection
#5

CJC-1295 / Ipamorelin

GH Secretagogue Combination • Research Peptide

CJC-1295 is a long-acting GHRH analog: in healthy adults it produced sustained, dose-dependent increases in growth hormone and IGF-I levels (PMID 16352683). Whether the combination with ipamorelin reduces body fat or body weight has not been tested in controlled trials, so any fat-loss effect is unquantified.

It is usually marketed as a body composition tool, often used alongside a caloric deficit and resistance training program.

Fat Loss: Not trial-tested
FDA Status: Not approved
Route: Daily SubQ (before bed)
#6

AOD-9604

HGH Fragment • Weak Evidence

AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) that was hypothesized to promote fat metabolism without GH's side effects. However, there is no strong clinical evidence that it produces meaningful weight loss in humans.

Not recommended as a primary weight loss peptide based on current evidence.

Weight Loss: No strong clinical evidence
FDA Status: Not approved
Evidence: Weak / unproven

Who Researches Weight Loss Peptides?

This Research Is Commonly Explored By People Who...

  • Want a comprehensive comparison of all peptides studied for weight management in one place
  • Are trying to understand the differences between GLP-1, GIP, and growth hormone peptide mechanisms
  • Have been overwhelmed by marketing claims and want to see what the actual clinical data shows
  • Are discussing options with a healthcare provider and want to be an informed participant
  • Are interested in both approved therapies and research-stage compounds for context

This Research May Not Be Relevant If...

  • You're looking for a specific recommendation — this is a research comparison, not a prescription guide
  • You want to self-administer peptides without medical oversight — we strongly advise against this
  • You have no weight-related health concerns and are looking for cosmetic enhancements
📚

Want the Complete Protocol Guide?

Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.


Get the Guide: $19 (normally $29) →
The GLP-1 Owner’s Manual ($19)

Key Takeaways

What's Clear

  • GLP-1 agonists are the gold standard for weight loss
  • Tirzepatide > semaglutide in head-to-head data
  • Retatrutide: 25.0% mean weight loss in Phase 3 TRIUMPH-1 (treatment-regimen estimand, PMID 42814954; cross-trial rankings are approximate; not yet FDA-approved)
  • Research GH peptides (CJC-1295/Ipamorelin, AOD-9604) lack strong clinical evidence for weight loss
  • All effective options require ongoing use to maintain
  • Diet + exercise still matter alongside any peptide

Important Caveats

  • Cross-trial comparisons are approximate
  • Individual response varies dramatically
  • Part of the weight lost can be lean mass (muscle)
  • Weight regain after discontinuation is significant
  • Long-term safety data still accumulating
  • Cost and insurance coverage vary widely

Weight Loss Support

Tools to maximize your weight loss results

Affiliate links support HighPeptides at no extra cost.

Trusted Vendor

Research-Grade Peptides

Third-party tested compounds with certificates of analysis. Used by researchers worldwide.

Browse Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost.

⚕️ Medical Disclaimer: This page is for educational and informational purposes only. It is not medical advice. Semaglutide and tirzepatide are FDA-approved prescription medications. Retatrutide is investigational. Other peptides listed are research compounds without FDA approval for weight loss. Always consult a qualified healthcare provider for weight management decisions.
📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.